

Formula I

or a pharmaceutically acceptable salt thereof, wherein: Z is $-OR^1$ or $-NR^2R^3$; R^1 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; R^2 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; and R^3 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl, or R^2 and R^3 are taken together with the atom to which they are attached to form an optionally substituted heterocycloalkyl; and the compound is administered at least once a week for at least two weeks.

[0006a] In one aspect, the present disclosure refers to use of a compound selected from Compound Nos. 1-7:



Compound 1



Compound 2



Compound 3



Compound 4



Compound 5



Compound 6



Compound 7

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating cancer in an individual, wherein the individual is human and the compound is to be administered at least once a week for at least two weeks.

[0007] In some examples, the compound is administered at least two times a week, including for example, at least three times a week. In some examples, the compound is administered three times a week.

[0008] In some examples according to any aforementioned method, the compound is administered for at least three consecutive days during a week, including for example, on days 1, 2, and 3 of each week. In some examples, the compound is administered once every other day during a week, including for example, on days 1, 3, and 5 of each week. In some examples, the compound is administered daily for at least two weeks.

[0009] In some examples, the compound is administered at least once a week for at least two weeks, including for example, at least once a week for two weeks with one week of rest in a 21-day dosage cycle.

[0010] In some examples, the compound is administered at least once a week for at least three weeks, including for example, at least once a week for three weeks with one week of rest in a 28-day dosage cycle.

[0011] In some examples according to any aforementioned method, the compound is administered at the dosage range of about 0.01 mg/m^2 to about 2 mg/m^2.

What is claimed is:

1. Use of a compound selected from Compound Nos. 1-7:



Compound 1



Compound 2



Compound 3



Compound 4



Compound 5



Compound 6



Compound 7

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating cancer in an individual, wherein the individual is human and the compound is to be administered at least once a week for at least two weeks.

2. The use of claim 1, wherein the compound is to be administered at least two times a week.

3. The use of claim 1, wherein the compound is to be administered at least three times a week.

4. The use of claim 3, wherein the compound is to be administered for at least three consecutive days during a week.

5. The use of claim 3, wherein the compound is to be administered once every other day during a week.

6. The use of claim 3, wherein the compound is to be administered three times a week.

7. The use of claim 4, wherein the compound is to be administered on days 1, 2, and 3 of each week.

8. The use of claim 5, wherein the compound is to be administered on days 1, 3, and 5 of each week.

9. The use of claim 3, wherein the compound is to be administered daily for at least two weeks.

10. The use of any one of claims 1-8, wherein the compound is to be administered at least once a week for at least two weeks.

11. The use of any one of claims 1-8, wherein the compound is to be administered at least once a week for at least three weeks.

12. The use of claim 10, wherein the compound is to be administered at least once a week for two weeks with one week of rest in a 21-day dosage cycle.

13. The use of claim 11, wherein the compound is to be administered at least once a week for three weeks with one week of rest in a 28-day dosage cycle.

14. The use of any one of claims 1-13, wherein the compound is to be administered at the dosage range of 0.02 mg/m^2 to 2 mg/m^2.

15. The use of any one of claims 1-13, wherein the compound is to be administered at the dosage range of 0.2 mg/m^2 to 2 mg/m^2.

16. The use of any one of claims 1-15, wherein the total dose of the compound to be administered to the individual is at least 0.4 mg/m^2 per week.

17. The use of any one of claims 1-16, wherein the cancer is selected from the group consisting of colorectal cancer, liver cancer, lung cancer, breast cancer, prostate cancer, pancreatic

cancer, and oral cancer.

18. The use of any one of claims 1-16, wherein the cancer is selected from the group consisting of colorectal cancer, breast cancer, liver cancer, gastric cancer, and non-small cell lung cancer.
19. The use of any one of claims 1-18, wherein the cancer is locally advanced or metastatic cancer.
20. The use of any one of claims 1-19, wherein the compound is to be administered intravenously.
21. The use of claim 20, wherein the compound is to be administered by infusion for at least 30 minutes at each administration.
22. The use of claim 20, wherein the compound is to be administered by infusion for at least 2 hours at each administration.
23. The use of claim 20, wherein the compound is to be administered continuously by infusion for at least 24 hours at each administration.
24. The use of any one of claims 1-23, wherein the individual has a high level of PI3K and/or pAKT.
25. The use of any one of claims 1-24, wherein the individual has progressed on or failed at least one prior systemic therapy.
26. The use of any one of claims 1-25, wherein the compound is to be administered at the concentration of 0.002 mg/mL to 0.01 mg/mL.
27. The use of any one of claims 1-26, wherein the compound is in a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
28. The use of claim 27, wherein the pharmaceutically acceptable carrier comprises an acetate or acetic acid.